Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors-Reference-Cited by-同舟云学术

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

Published:2019-12-10 Issue:1 Volume:63 Page:52-65
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lanman Brian A.^ORCID,Allen Jennifer R.,Allen John G.,Amegadzie Albert K.,Ashton Kate S.,Booker Shon K.,Chen Jian Jeffrey,Chen Ning,Frohn Michael J.,Goodman Guy,Kopecky David J.,Liu Longbin,Lopez Patricia,Low Jonathan D.,Ma Vu,Minatti Ana E.,Nguyen Thomas T.,Nishimura Nobuko,Pickrell Alexander J.,Reed Anthony B.,Shin Youngsook^ORCID,Siegmund Aaron C.,Tamayo Nuria A.,Tegley Christopher M.,Walton Mary C.,Wang Hui-Ling^ORCID,Wurz Ryan P.^ORCID,Xue May,Yang Kevin C.,Achanta Pragathi,Bartberger Michael D.^ORCID,Canon Jude,Hollis L. Steven,McCarter John D.,Mohr Christopher,Rex Karen,Saiki Anne Y.,San Miguel Tisha,Volak Laurie P.,Wang Kevin H.,Whittington Douglas A.^ORCID,Zech Stephan G.,Lipford J. Russell,Cee Victor J.^ORCID

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b01180

Reference25 articles.

1. Drugging the undruggable RAS: Mission Possible?

2. RAS isoforms and mutations in cancer at a glance

3. A Comprehensive Survey of Ras Mutations in Cancer

4. Efforts to Develop KRAS Inhibitors

5. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Cited by 464 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiscale calculations reveal new insights into the reaction mechanism between KRASG12C and α, β-unsaturated carbonyl of covalent inhibitors;Computational and Structural Biotechnology Journal;2024-12

2. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers;European Journal of Medicinal Chemistry;2024-11

3. Hit me with your best shot: Integrated hit discovery for the next generation of drug targets;Drug Discovery Today;2024-10

4. ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer;EMBO Molecular Medicine;2024-09-13

5. SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers;Nature Communications;2024-09-12